Carrier Screening Market Report Scope & Overview:

The Carrier Screening Market was valued at USD 2.41 Billion in 2025 and is expected to reach USD 7.45 Billion by 2035, growing at a CAGR of 11.94% from 2026-2035.

The Carrier Screening Market covers genetic tests that show whether a healthy person carries a gene change linked to an inherited disease, so couples can understand the chance of passing a condition to a child. Tests range from single-disease checks for cystic fibrosis or spinal muscular atrophy to expanded panels covering hundreds of genes. Growth is supported by lower sequencing cost, professional guidance that recommends offering screening to all pregnant and planning couples, and fertility care, while cost, counseling capacity and coverage shape adoption.

⮞In September, 2025, PacBio expanded its PureTarget portfolio with a carrier screening panel using HiFi long-read sequencing. The research-use kits cover difficult genes such as FMR1, SMN1 and FXN, are offered in 24- and 96-sample formats, and can process up to 100,000 samples a year on a single Revio system.

To Get more information Carrier Screening Market - Request Free Sample Report

U.S. Carrier Screening Market Outlook

The U.S. Carrier Screening Market was valued at USD 0.89 Billion in 2025 and is expected to reach USD 2.39 Billion by 2035, growing at a CAGR of 10.40% from 2026-2035.

The U.S. Carrier Screening Market is the largest national market, supported by professional guidelines that encourage offering screening to all pregnant patients and couples planning pregnancy, a large fertility sector and strong laboratory networks. Insurers cover screening for many patients, and laboratories compete on panel size, turnaround time and price. Growth is moderated by variation in coverage, limited genetic counselor capacity and debate about the clinical value of very large panels.

⮞In August, 2025, Natera launched Fetal Focus, a noninvasive prenatal test that uses a maternal blood sample to look for inherited conditions in the fetus, including cystic fibrosis. The test is designed for pregnancies where the parents are known or suspected carriers, linking carrier results to follow-up testing.

By Type, Expanded Carrier Screening Dominates Carrier Screening Market; Customized Panels to Register Fastest Growth.

Expanded carrier screening dominates the Carrier Screening Market because panels that cover hundreds of genes are priced close to single-disease tests and detect more couples at risk. Professional guidance has moved toward offering broader screening regardless of ancestry, and laboratories now bundle conditions in one workflow. Physicians value the simplicity of ordering one test instead of choosing diseases one at a time. Laboratories also benefit from batching samples, which lowers costs per patient and supports price competition among large providers. Software that sorts results into clear reports helps clinicians explain risk to couples who have no genetic background.

Customized panels are projected to register the fastest growth as clinics and health systems design tests around local disease patterns, family history and patient preference. Fertility centers, population programs and insurers want control over which genes are reported, and sequencing platforms make panel changes easy. Flexible reporting, tiered pricing and links to counseling support this approach. Insurers and employers are also beginning to ask for flexible options, which encourages laboratories to publish gene lists and let physicians pick tiers. Partnerships with fertility networks and donor banks add further volume for tailored tests.

By Technology, Next-Generation Sequencing Dominates Carrier Screening Market; Long-Read Sequencing to Register Fastest Growth.

Next-generation sequencing dominates the Carrier Screening Market because it reads many genes in one run, detects rare variants and scales to large sample volumes at falling cost. Laboratories have invested in sequencers, software and trained staff, and results can be reanalyzed as knowledge grows. The method also supports expanded panels that older techniques could not offer at reasonable prices. Streamlined library preparation and automated analysis also reduce hands-on time for staff, which matters in laboratories handling thousands of samples each week. Cloud-based pipelines allow quick updates when variant databases change.

Long-read sequencing is projected to register the fastest growth as it reads difficult genes that short reads can miss, including repeat expansions and genes with similar copies, such as those linked to fragile X, spinal muscular atrophy and Friedreich ataxia. Consolidating several special assays into one workflow can save laboratories time. Higher throughput and lower cost per sample are making the method more attractive. Vendors are also bundling reagents, instruments and analysis software, so a laboratory can validate one workflow for several hard genes. Early adopters report fewer repeat tests and shorter reporting times, which may encourage wider use.

By Medical Condition, Cystic Fibrosis Dominates Carrier Screening Market; Spinal Muscular Atrophy to Register Fastest Growth.

Cystic fibrosis dominates the Carrier Screening Market because it was among the first conditions for which carrier testing was recommended and remains part of nearly every panel. It is common in people of European descent and has well-defined variants, so results are straightforward to interpret. Long-standing guidelines and patient awareness keep testing volumes high. Industry laboratories also publish carrier frequency data from large patient groups, which helps clinicians interpret risk. Patient groups and charities raise awareness, and early detection gives families time to plan for care and treatment.

Spinal muscular atrophy is projected to register the fastest growth as guidelines recommend offering testing to all couples and as new treatments make early knowledge more valuable. Technology to detect copy numbers of the SMN1 gene is improving, and laboratories are adding it to standard panels. Rising newborn screening programs also increase awareness among parents and physicians. Therapies that can be started early in life, together with newborn screening, increase the importance of identifying carrier couples. Clinics also report that the test is among the easiest to explain, since a simple copy number result is often enough.

By End User, Reference Laboratories Dominates Carrier Screening Market; Specialty Fertility Centers to Register Fastest Growth.

Reference laboratories dominate the Carrier Screening Market because they have sequencing capacity, bioinformatics, genetic counselors and contracts with health plans and providers. Obstetric practices and clinics send samples to these laboratories rather than build their own. Scale lowers the price per test and allows quick turnaround for patients who are already pregnant. Large laboratory groups with national sales teams can market directly to obstetricians and fertility specialists, supported by online ordering portals and electronic health record links that make requests simple for busy practices.

Specialty fertility centers are projected to register the fastest growth as couples undergoing in vitro fertilization often want to know carrier status before choosing embryos. Clinics partner with laboratories to offer screening during the first consultation. Rising demand for fertility care, later childbearing and egg or sperm donor screening support steady growth in this setting. Genetic counseling services, including telehealth options, are often bundled with tests to ease strain on clinic staff. Egg freezing, surrogacy and gamete donation also add to the number of individuals who are screened each year.

Regional Analysis

North America Carrier Screening Market Insights

North America dominated revenue with a share of 41.00% in 2025. The United States accounts for major share of regional demand, with Canada adding volume. Natera, Myriad Genetics, Labcorp, Quest Diagnostics, Illumina, Fulgent Genetics, GeneDx, Ambry Genetics and Pacific Biosciences serve the region. Employer benefits, direct-to-consumer ordering and telehealth counseling are increasing the number of access points. Large laboratories also acquire smaller companies to broaden their test menus and sales reach.

Professional guidelines, wide insurance coverage and a large fertility industry support leadership. Laboratories compete on turnaround time, panel size and integration with prenatal tests. Variation in coverage, limited genetic counselor capacity and questions about very large panels moderate growth, though consumer awareness and employer fertility benefits continue to add demand. State programs, medical societies and patient advocacy groups publish recommendations that raise awareness among clinicians, and partnerships between sequencing makers and clinical laboratories keep innovation active. Competition on price has narrowed margins, so companies emphasize automation and software to protect profit.

Get Customized Report as per Your Business Requirement - Enquiry Now

Asia Pacific Carrier Screening Market Insights

Asia Pacific is projected to be the fastest-growing region, at a CAGR of 14.80% during 2026-2035. China leads regional demand, followed by India, Japan, South Korea, Australia and Southeast Asia. BGI Genomics, MedGenome, Gene Solutions, Macrogen, Illumina and Thermo Fisher Scientific are among the participants. Thalassemia and other recessive conditions are common in the region, which raises the value of screening. Japan, South Korea and Australia are the most mature markets, while China and India offer scale. Local sequencing producers are lowering prices, which supports adoption outside large cities.

Large birth cohorts, rising fertility treatment, growing prenatal testing infrastructure and government programs support growth. Providers are adding carrier screening to existing prenatal blood tests to reach more women. Cost sensitivity, limited genetic counseling and differing regulations across countries moderate growth, but rising incomes and awareness are widening the user base. Public health programs for thalassemia and other inherited blood disorders in several countries already include carrier checks, which creates a base for broader panels and builds familiarity among physicians.

⮞In July 22, 2026, Gene Solutions reported at ISPD 2026 that 225,092 pregnant women in Vietnam, the Philippines, Indonesia, Malaysia, Taiwan and India were screened for 18 recessive conditions through routine NIPT between February 2025 and February 2026. More than one in four carried at least one condition, and the company's triSure Procare adds maternal carrier screening to NIPT.

Europe Carrier Screening Market Insights

In Europe Germany, the United Kingdom, France, Italy and Spain lead regional demand. CENTOGENE, Eurofins Scientific, Blueprint Genetics, Illumina, Thermo Fisher Scientific and national laboratories supply tests to hospitals and fertility clinics. Several countries run population programs for specific conditions, and research consortia are building shared variant databases. University hospitals often develop and validate their own tests before offering them widely. Local sequencing partnerships and academic research centers also add testing capacity and clinical expertise.

National health systems vary in whether they fund carrier screening, so private clinics and fertility centers account for much of the demand. Data protection rules and ethical review shape how panels are offered. Public funding limits, differing guidelines between countries and low awareness moderate growth, though cross-border fertility care supports volumes. Companies also work with fertility networks that operate across borders, allowing a single laboratory to serve clinics in many countries. Language support and common reporting formats make this model efficient.

⮞In May, 2026, CENTOGENE introduced CentoScreen Exome and updated its CentoScreen Genome offers for family planning. CentoScreen Genome screens over 60,000 variants in 1,921 genes with a turnaround of 15 business days, and a comprehensive version for high-risk couples covers more than 2,000 genes linked to recessive and X-linked early-onset disorders.

MEA & Latin America Carrier Screening Market Insights

In Latin America, Brazil leads, followed by Mexico, Argentina, Colombia and Chile. Private fertility clinics and laboratory chains are the main buyers, and international laboratories partner with local providers. Cost and limited public funding restrain use. International laboratories often ship samples to centers in the United States or Europe, which adds time and cost. Local processing partnerships are emerging, and distributors help train physicians on ordering and interpreting results. Awareness campaigns by medical societies and hospital genetics units are slowly widening the pool of informed patients.

In the Middle East and Africa, Saudi Arabia, the United Arab Emirates, Qatar, Egypt and South Africa lead demand. High rates of recessive conditions linked to consanguinity and premarital screening programs raise interest in broader testing, while uneven access outside the Gulf limits growth. Government investment in genomic centers in the Gulf is building local capacity, and regional programs on inherited blood disorders create awareness that can be extended to broader screening. Reimbursement is limited in most public systems, so private pay and employer-supported fertility plans drive early adoption.

Market Dynamics

Growth Drivers: Lower Sequencing Cost, Guidelines and Fertility Care

Falling sequencing costs let laboratories offer broad panels at prices close to single-disease tests, and professional guidance encourages offering screening to all couples. Public awareness of genetic disease is also growing through patient groups and media coverage. Clinics also report that partners are more willing to test when results are available within two weeks and costs are clear at the time of ordering.

Growth in fertility treatment, later parenthood and prenatal testing creates natural points to offer carrier screening alongside other services. Wider insurer coverage of fertility services further adds to the number of eligible patients.

Restraints: Counseling Capacity, Coverage Gaps and Ethical Concerns

Genetic counselors are in short supply, and many results need explanation, which limits how quickly screening can expand. Many patients also prefer not to learn about conditions that are untreatable, which limits take-up of very large panels. Variants of uncertain significance can also confuse patients and increase the number of follow-up visits for each test.

Coverage varies by country and payer, and debate over the value of very large panels and over reporting of minor findings can slow adoption. Privacy concerns about storage of genetic data add further hesitation among some couples.

Opportunities: Long-Read Sequencing, Population Programs and Emerging Markets

Long-read methods allow reliable testing of genes that were hard to read, and integration with prenatal blood tests can reach more patients. Digital tools that deliver results and education online can also reduce counseling load. Lower-cost kits designed for resource-limited settings could make screening available in public clinics.

Population genomic programs and premarital screening, together with rising incomes in Asia Pacific and the Middle East, offer large new groups of potential users. Collaboration with fertility networks and health systems provides routes to patients at scale. Digital education tools and decision aids can help couples prepare before consultations and reduce anxiety about results.

Carrier Screening Market Key Players are:

• Natera, Inc.

• Myriad Genetics, Inc.

• Illumina, Inc.

• Thermo Fisher Scientific Inc.

• Laboratory Corporation of America Holdings (Labcorp)

• Quest Diagnostics Incorporated

• Fulgent Genetics, Inc.

• GeneDx Holdings Corp.

• Eurofins Scientific SE

• CENTOGENE N.V.

• BGI Genomics Co., Ltd.

• MedGenome Labs Ltd.

• OPKO Health, Inc.

• Ambry Genetics (Tempus AI, Inc.)

• Baylor Genetics

• Pacific Biosciences of California, Inc.

• Gene Solutions

• Color Health, Inc.

• Blueprint Genetics

• Revvity, Inc.

Carrier Screening Market Report Scope: